WCM
URGN icon

Weld Capital Management’s UroGen Pharma URGN Stock Holding History

Weld Capital Management’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-6,116
Closed -$220K – 1022
2019
Q2 		$220K Buy
+6,116
New +$225K 0.04% 624

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Weld Capital Management's URGN Position: Q3 2019 in Review

Weld Capital Management sold out of UroGen Pharma (URGN) in Q3 2019, closing a stake of 6,116 shares — an estimated $220K sold.

Weld Capital Management first reported a position in URGN in Q2 2019 and held it in 1 quarter. The position peaked at $220K in Q2 2019. 84 funds tracked by Wall St. Rank hold URGN as of Q3 2019.

  • Weld Capital Management reported no remaining UroGen Pharma position as of Q3 2019 after selling out during the quarter.
  • Weld Capital Management sold 6,116 UroGen Pharma shares in Q3 2019, an estimated $220K.
  • Weld Capital Management first reported a position in UroGen Pharma in Q2 2019 and held it in 1 quarter.
  • Weld Capital Management's UroGen Pharma position peaked at $220K in Q2 2019.
  • 84 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2019.

Based on Weld Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.